1
|
Tang T, Luo X, Li N, Li Q, Zhang M, Zeng J, Song H, Li L, Chen W. A developed and validated centrifugal ultrafiltration coupled with high performance liquid chromatography-tandem mass spectrometry method for rapid quantification of unbound lenvatinib in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2024; 1240:124157. [PMID: 38761468 DOI: 10.1016/j.jchromb.2024.124157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2023] [Revised: 04/20/2024] [Accepted: 05/13/2024] [Indexed: 05/20/2024]
Abstract
In clinical practice, the determination of unbound drug concentration is very important for dose adjustment and toxicity prediction because only the unbound fraction can achieve a pharmacological effect. A fast, sensitive and accurate analytical method of centrifugal ultrafiltration coupled with high performance liquid chromatography-tandem mass spectrometry method was developed and applied to allow the quantification of unbound lenvatinib concentration. The application of linear regression analysis was used to examine the effects of centrifugal force, centrifugal time, and protein content on ultrafiltrate volume (Vu). The results indicated that the centrifugal force and centrifugal time have an influence on Vu that is significantly positive (P < 0.05). This developed method with good linearity (r2 = 0.9996), good accuracy (bias % ≤ 2.24 %), good precision (CV % ≤ 7.10 %), and good recovery (95.46 %-106.46 %) was suitable for routine clinical practice and studies. Particularly, the ultrafiltration membrane had no non-specific binding to lenvatinib. The unbound fractions can be separated in just 15 min. This method was applied to quantify clinical samples and to determine the plasma protein binding and unbound fraction of lenvatinib. This study provides a more effective and promising method for determination of unbound lenvatinib. It could be beneficial to measure the unbound concentration of lenvatinib in personalized medicine and therapeutic drug monitoring in routine clinical practice.
Collapse
Affiliation(s)
- Tiantian Tang
- Department of Pharmacy, Chongqing University Cancer Hospital, Chongqing 400030, China
| | - Xianzhang Luo
- Hepatic Biliary & Pancreatic Cancer Center, Chongqing University Cancer Hospital, Chongqing 400030, China
| | - Na Li
- Department of Pharmacy, Chongqing University Cancer Hospital, Chongqing 400030, China
| | - Qiaoqiao Li
- Department of Pharmacy, Chongqing University Cancer Hospital, Chongqing 400030, China
| | - Min Zhang
- Department of Pharmacy, Chongqing University Cancer Hospital, Chongqing 400030, China
| | - Jin Zeng
- Department of Pharmacy, Chongqing University Cancer Hospital, Chongqing 400030, China
| | - Haichi Song
- Department of Pharmacy, Chongqing University Cancer Hospital, Chongqing 400030, China
| | - Lixian Li
- Department of Pharmacy, Chongqing University Cancer Hospital, Chongqing 400030, China.
| | - Wanyi Chen
- Department of Pharmacy, Chongqing University Cancer Hospital, Chongqing 400030, China.
| |
Collapse
|
2
|
Abdalla S, Compagnucci A, Riault Y, Chan MK, Bamford A, Nolan A, Ramos JT, Constant V, Nguyen TN, Zheng Y, Tréluyer JM, Froelicher-Bournaud L, Neveux N, Saidi Y, Cressey TR, Hirt D. Simultaneous pharmacokinetic modeling of unbound and total darunavir with ritonavir in adolescents: a substudy of the SMILE trial. Antimicrob Agents Chemother 2024; 68:e0100423. [PMID: 38092664 PMCID: PMC10848770 DOI: 10.1128/aac.01004-23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2023] [Accepted: 11/14/2023] [Indexed: 02/08/2024] Open
Abstract
Darunavir (DRV) is an HIV protease inhibitor commonly used as part of antiretroviral treatment regimens globally for children and adolescents. It requires a pharmacological booster, such as ritonavir (RTV) or cobicistat. To better understand the pharmacokinetics (PK) of DRV in this younger population and the importance of the RTV boosting effect, a population PK substudy was conducted within SMILE trial, where the maintenance of HIV suppression with once daily integrate inhibitor + darunavir/ritonavir in children and adolescents is evaluated. A joint population PK model that simultaneously used total DRV, unbound DRV, and total RTV concentrations was developed. Competitive and non-competitive models were examined to define RTV's influence on DRV pharmacokinetics. Linear and non-linear equations were tested to assess DRV protein binding. A total of 443 plasma samples from 152 adolescents were included in this analysis. Darunavir PK was best described by a one-compartment model first-order absorption and elimination. The influence of RTV on DRV pharmacokinetics was best characterized by ritonavir area under the curve on DRV clearance using a power function. The association of non-linear and linear equations was used to describe DRV protein binding to alpha-1 glycoprotein and albumin, respectively. In our population, simulations indicate that 86.8% of total and unbound DRV trough concentrations were above 0.55 mg/L [10 times protein binding-adjusted EC50 for wild-type (WT) HIV-1] and 0.0243 mg/L (10 times EC90 for WT HIV-1) targets, respectively. Predictions were also in agreement with observed outcomes from adults receiving 800/100 mg DRV/r once a day. Administration of 800/100 mg of DRV/r once daily provides satisfactory concentrations and exposures for adolescents aged 12 years and older.
Collapse
Affiliation(s)
- Seef Abdalla
- Pharmacologie et évaluation des thérapeutiques chez l'enfant et la femme enceinte, Université Paris Cité, Paris, France
- Service de Pharmacologie Clinique, Hôpital Cochin, APHP Centre–Université Paris Cité, Paris, France
| | - Alexandra Compagnucci
- SC10-US019 Essais Thérapeutiques et Maladies Infectieuses, INSERM, Villejuif, France
| | - Yoann Riault
- SC10-US019 Essais Thérapeutiques et Maladies Infectieuses, INSERM, Villejuif, France
| | - Man K. Chan
- MRC Clinical Trials Unit at UCL, London, United Kingdom
| | - Alasdair Bamford
- MRC Clinical Trials Unit at UCL, London, United Kingdom
- Paediatric Infectious Diseases, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom
| | - Aoife Nolan
- MRC Clinical Trials Unit at UCL, London, United Kingdom
| | - José T. Ramos
- Department of Pediatrics, Fundación de Investigación Biomédica Hospital Clínico San Carlos, Hospital Clínico San Carlos, Madrid, Spain
- Centro de Investigación Biomédica en Red en Enfermedades Infecciosas, Universidad Complutense de Madrid, Madrid, Spain
| | - Valentin Constant
- Pharmacologie et évaluation des thérapeutiques chez l'enfant et la femme enceinte, Université Paris Cité, Paris, France
| | - Thao-Nguyen Nguyen
- Pharmacologie et évaluation des thérapeutiques chez l'enfant et la femme enceinte, Université Paris Cité, Paris, France
| | - Yi Zheng
- Pharmacologie et évaluation des thérapeutiques chez l'enfant et la femme enceinte, Université Paris Cité, Paris, France
| | - Jean-Marc Tréluyer
- Pharmacologie et évaluation des thérapeutiques chez l'enfant et la femme enceinte, Université Paris Cité, Paris, France
- Service de Pharmacologie Clinique, Hôpital Cochin, APHP Centre–Université Paris Cité, Paris, France
- Unité de Recherche Clinique, Hôpital Necker Enfants Malades, APHP Centre–Université Paris Cité, Paris, France
| | - Léo Froelicher-Bournaud
- Pharmacologie et évaluation des thérapeutiques chez l'enfant et la femme enceinte, Université Paris Cité, Paris, France
- Service de Pharmacologie Clinique, Hôpital Cochin, APHP Centre–Université Paris Cité, Paris, France
| | - Nathalie Neveux
- Service de Biochimie, Hôpital Cochin, APHP Centre–Université Paris Cité, Paris, France
| | - Yacine Saidi
- SC10-US019 Essais Thérapeutiques et Maladies Infectieuses, INSERM, Villejuif, France
| | - Tim R. Cressey
- AMS-PHPT Research Collaboration, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand
- Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom
| | - Déborah Hirt
- Pharmacologie et évaluation des thérapeutiques chez l'enfant et la femme enceinte, Université Paris Cité, Paris, France
- Service de Pharmacologie Clinique, Hôpital Cochin, APHP Centre–Université Paris Cité, Paris, France
| | - on behalf of the SMILE study group
- Pharmacologie et évaluation des thérapeutiques chez l'enfant et la femme enceinte, Université Paris Cité, Paris, France
- Service de Pharmacologie Clinique, Hôpital Cochin, APHP Centre–Université Paris Cité, Paris, France
- SC10-US019 Essais Thérapeutiques et Maladies Infectieuses, INSERM, Villejuif, France
- MRC Clinical Trials Unit at UCL, London, United Kingdom
- Paediatric Infectious Diseases, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom
- Department of Pediatrics, Fundación de Investigación Biomédica Hospital Clínico San Carlos, Hospital Clínico San Carlos, Madrid, Spain
- Centro de Investigación Biomédica en Red en Enfermedades Infecciosas, Universidad Complutense de Madrid, Madrid, Spain
- Unité de Recherche Clinique, Hôpital Necker Enfants Malades, APHP Centre–Université Paris Cité, Paris, France
- Service de Biochimie, Hôpital Cochin, APHP Centre–Université Paris Cité, Paris, France
- AMS-PHPT Research Collaboration, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand
- Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom
| |
Collapse
|
3
|
Rigo-Bonnin R, García-Tejada L, Mas-Bosch V, Imaz A, Manuel Tiraboschi J, Scévola S, Niubó J, Navarro-Alcaraz A, Podzamczer D. Development and validation of equilibrium dialysis UHPLC-MS/MS measurement procedures for total and unbound concentrations of bictegravir, dolutegravir, darunavir and doravirine in human plasma. Application to patients with HIV. Clin Chim Acta 2024; 552:117678. [PMID: 38042460 DOI: 10.1016/j.cca.2023.117678] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2023] [Revised: 11/03/2023] [Accepted: 11/20/2023] [Indexed: 12/04/2023]
Abstract
BACKGROUND Fixed-dose combinations of antiretroviral drugs are commonly used to treat HIV infection and therapeutic monitoring is not part of routine clinical practice. However, drug concentrations monitoring might have role in different clinical scenarios as well as for research purposes. This study aimed to develop and validate UHPLC-MS/MS procedures for measuring total and unbound concentrations of bictegravir, dolutegravir, darunavir and doravirine in human plasma. MATERIAL AND METHODS Equilibrium dialysis preceded sample preparation (based on protein precipitation) for measuring unbound antiretroviral concentrations. Chromatographic separations were achieved on an Acquity®-UPLC® HSS™-T3 column (50 mm × 2.1 mm; 1.8 µm) using a non-linear water/acetonitrile gradient containing 0.1 % formic acid at a 0.5 mL/min flow rate. Antiretrovirals were detected by tandem mass spectrometry in positive electrospray ionisation and multiple reaction monitoring modes. RESULTS No significant interferences or carry-over were observed. Imprecisions, absolute relative biases, normalised matrix effects and recoveries were ≤15.0 %, ≤11.1 %, (94.7-104.1)% and (96.7-105.5)%, respectively. Non-linear measuring intervals were observed between (25-10,000) µg/L for total/plasma dialysate concentrations and linearity schemes (1.00-100) µg/L for buffer dialysate concentrations. CONCLUSIONS The UHPLC-MS/MS procedures developed could be used for research purposes and therapeutic drug monitoring of antiretrovirals in routine clinical practice.
Collapse
Affiliation(s)
- Raúl Rigo-Bonnin
- Department of Clinical Laboratory, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.
| | - Laura García-Tejada
- Department of Clinical Laboratory, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain
| | - Virgínia Mas-Bosch
- Department of Clinical Laboratory, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain
| | - Arkaitz Imaz
- Human Immunodeficiency Virus (HIV) and Sexually Transmitted Infection (STI) Unit, Department of Infectious Diseases, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain
| | - Juan Manuel Tiraboschi
- Human Immunodeficiency Virus (HIV) and Sexually Transmitted Infection (STI) Unit, Department of Infectious Diseases, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain
| | - Sofía Scévola
- Human Immunodeficiency Virus (HIV) and Sexually Transmitted Infection (STI) Unit, Department of Infectious Diseases, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain
| | - Jordi Niubó
- Department of Microbiology, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain
| | - Antonio Navarro-Alcaraz
- Human Immunodeficiency Virus (HIV) and Sexually Transmitted Infection (STI) Unit, Department of Infectious Diseases, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain; Microbial Genomics Group, IrsiCaixa-Institut de Recerca de la SIDA, Badalona, Spain
| | - Daniel Podzamczer
- Human Immunodeficiency Virus (HIV) and Sexually Transmitted Infection (STI) Unit, Department of Infectious Diseases, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain; FLScience, Fight Infections Foundation, Badalona, Spain
| |
Collapse
|